As a consequence of the multitude of options for treatment of disseminated prostate cancer [128], late-stage patients have highly variable treatment histories that jeopardize good clinical evaluation of the most optimal timing of GRPR and PSMA imaging (and therapy) in these patients. This evidence concerns the gene FOLH1 and prostate cancer.